The effect of simvastatin treatment on plasma ubiquinone, blood ATP concentrations, total antioxidant capacity and muscle related markers

Turkish Journal of Medical Sciences

Volumn 32, Issue 4, 2002, Pages 323-328

  Altekýn, Emel ^a   Önvural, Banu ^a   Çoker, Canan ^a   Günerý, Sema ^a   Çalikan, Sezer ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

Antioxidant; ATP; HMG CoA reductase inhibitors; Ubiquinone

Indexed keywords

ADENOSINETRIPHOSPHATE; ANTIOXIDANTS; BIOMARKERS; CHOLESTEROL; ELECTRON TRANSPORT PROPERTIES; METABOLISM; MUSCLE; PATIENT TREATMENT;

STATINS;

BLOOD;

ADENOSINE TRIPHOSPHATE; CHOLESTEROL; CREATINE KINASE; MYOGLOBIN; SIMVASTATIN; UBIQUINONE;

ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; DRUG EFFECT; ELECTRON TRANSPORT; HUMAN; HYPERCHOLESTEROLEMIA; MALE; MUSCLE DISEASE;

EID: 0036070085     PISSN: 13000144     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia
2. Regulation of the mevalonate pathway
3. Low serum total cholesterol concentrations and mortality in middle aged British men
4. Commentary: Having too much evidence (depression, suicide and low serum cholesterol)
5. Plasma coenzyme Q (ubiquinone) concentrations in patients treated with simvastatin
6. Ubiquinol: Endogenous antioxidant in aerobic organism
7. Regulation of ubiquinone metabolism
8. Rhabdomyolysis secondary to lovastatin therapy
9. Potential risk of myopathy by HMG-CoA reductase inhibitors: A comparison of pravastatin and simvastatin effects on membrane electrical properties of rat skeletal muscle fibers
10. Intraoperative rhabdomyolysis in a patient receiving pravastatin, a 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitor
11. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge
12. 10 in plasma
13. Adenosine-5′-triphosphate determination with phosphogylcerate kinase
14. A novel method for measuring antioxidant capacity and its application to monitoring the antioxidant status in premature neonates
15. Serum ubiquinone concentrations after short- and long-term treatment with HMG-CoA reductase inhibitors
16. Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans
17. 10-lowering effect by HMG-CoA reductase inhibitors: A double-blind, placebo-controlled study
18. Lovastatin decreases coenzyme Q levels in rats
19. Effect of simvastatin therapy on blood and tissue ATP levels and erythrocyte membrane lipid composition
20. The effects of simvastatin treatment on natural antioxidants in low-density lipoproteins and high energy phosphates and ubiquinone in skeletal muscle
21. Biochemical, physiological and medical aspects of ubiquinone function
22. Myopathy induced by HMG CoA reductase inhibitors in rabbits: A pathological, electrophysiological, and biochemical study
23. Simvastatin-induced rhabdomyolysis followed by a MELAS syndrome
24. HMG-CoA Reductase inhibitor-induced myopathy in the rat: Cyclosporine A interaction and mechanism studies
25. Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin
26. Rhabdomyolysis due to interaction of simvastatin with mibefradil
27. HMG-CoA reductase inhibitors: Assessing differences in drug interactions and safely profiles
28. Ubiquinone supplementation during lovastatin treatment: Effect on LDL oxidation ex vivo
29. Antioxidant effects of ubiquinones in microsomes and mitochondria are mediated by tocopherol recycling
30. Biochemical and physiological aspects of ubiquinone function
31. Serum cholesterol concentration and death from suicide in men: Paris prospective study 1
32. Serum cholesterol concentration and risk of brain cancer
33. Systematic review on the risk and benefit of different cholesterol-lowering interventions
34. Influence of baseline lipids on effectiveness of pravastatin in the CARE trial
35. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Survival Study (4S)
36. Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects
37. Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects
38. Plasma coenzyme Q10 concentrations in breast cancer: Prognosis and therapeutic consequences
39. CQ10: Could it have a role in cancer management